Natalizumab for active Crohn's disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Leukocyte migration in chronic inflammation, like Crohn's disease, is partly regulated by alpha4 integrins.
• Alpha4 integrins play a role in leukocyte trafficking to inflammatory sites.

Purpose of the Study:

• To evaluate the efficacy and safety of natalizumab, an alpha4 integrin-specific antibody, in patients with moderate-to-severe Crohn's disease.
• To assess natalizumab's impact on clinical remission, response rates, quality of life, and C-reactive protein levels.

Main Methods:

• A double-blind, placebo-controlled trial involving 248 patients with moderate-to-severe Crohn's disease.
• Random assignment to four treatment groups: placebo, one or two infusions of 3 mg/kg natalizumab, or two infusions of 6 mg/kg natalizumab.
• Outcomes measured included Crohn's Disease Activity Index scores, quality of life, and C-reactive protein levels.

Main Results:

• While the primary endpoint of clinical remission at week 6 was not significantly higher in the 6 mg/kg natalizumab group, both natalizumab groups showed improved remission rates over placebo.
• Significant improvements in response rates (≥70-point reduction in CDAl) were observed with natalizumab.
• Quality of life and C-reactive protein levels improved in patients receiving natalizumab; adverse event rates were similar across all groups.

Conclusions:

• Natalizumab, a selective adhesion-molecule inhibitor, effectively increased clinical remission and response rates in active Crohn's disease.
• Treatment with natalizumab improved quality of life and C-reactive protein levels.
• Natalizumab was well-tolerated in patients with active Crohn's disease.